Education
About Us
Working with TipRanks
Follow Us
Elekta AB (EKTAY)
OTHER OTC:EKTAY
EKTAY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.43 - $8.30
Previous CloseN/A
Volume122.00
Average Volume (3M)1.55K
Market Cap
$1.97B
Enterprise Value$2.85B
Total Cash (Recent Filing)kr3.58B
Total Debt (Recent Filing)kr8.86B
Price to Earnings (P/E)20.2
Beta0.89
Next Earnings
May 28, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 07, 2025Dividend Yield2.28%
Share Statistics
EPS (TTM)0.25
Shares Outstanding368,588,000
10 Day Avg. Volume0
30 Day Avg. Volume1,547
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.06
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Elekta AB News
PremiumCompany Announcements
Elekta AB Reports Solid Q3 Growth and Record Cash Flow
PremiumCompany Announcements
Elekta AB Earnings Call Highlights: Growth Amid Challenges
PremiumCompany Announcements
Elekta AB Q2 2024/25 Earnings Report Overview---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.02%
Mutual Funds
<0.01% Other Institutional Investors
99.97% Public Companies and
Individual Investors
EKTAY FAQ
What was Elekta AB’s price range in the past 12 months?
Elekta AB lowest stock price was $4.43 and its highest was $8.30 in the past 12 months.
What is Elekta AB’s market cap?
Elekta AB’s market cap is $1.97B.
When is Elekta AB’s upcoming earnings report date?
Elekta AB’s upcoming earnings report date is May 28, 2025 which is in 30 days.
How were Elekta AB’s earnings last quarter?
Elekta AB released its earnings results on Feb 21, 2025. The company reported $0.081 earnings per share for the quarter, beating the consensus estimate of N/A by $0.081.
Is Elekta AB overvalued?
According to Wall Street analysts Elekta AB’s price is currently Overvalued.
Does Elekta AB pay dividends?
Elekta AB pays a Semiannually dividend of $0.122 which represents an annual dividend yield of 2.28%. See more information on Elekta AB dividends here
What is Elekta AB’s EPS estimate?
Elekta AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elekta AB have?
Elekta AB has 368,588,000 shares outstanding.
What happened to Elekta AB’s price movement after its last earnings report?
Elekta AB reported an EPS of $0.081 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -8.632%.
Which hedge fund is a major shareholder of Elekta AB?
Currently, no hedge funds are holding shares in EKTAY
---
Elekta AB Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.46%
12-Months-Change
Fundamentals
Return on Equity
9.90%
Trailing 12-Months
Asset Growth
0.18%
Trailing 12-Months
Company Description
Elekta AB
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
---
EKTAY Company Deck
---
EKTAY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with notable achievements in product launches and order growth, particularly in Europe, alongside challenges in the U.S. and China markets and reduced EBIT margin guidance.Read More>---
EKTAY Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---